EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Leap Therapeutics's enterprise value is €32.70 Mil.
Leap Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was €-49.84 Mil. Therefore, Leap Therapeutics's EV-to-EBITDA for today is -0.66.
The historical rank and industry rank for Leap Therapeutics's EV-to-EBITDA or its related term are showing as below:
FRA:5MC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.34 Med: -1.08 Max: 1.17
Current: -0.66
During the past 12 years, the highest EV-to-EBITDA of Leap Therapeutics was 1.17. The lowest was -7.34. And the median was -1.08.
FRA:5MC's EV-to-EBITDA is ranked worse than 100% of 449
companies
in the Biotechnology industry
Industry Median: 9.2
vs FRA:5MC: -0.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Leap Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Leap Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Leap Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Leap Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leap Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Leap Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Leap Therapeutics's EV-to-EBITDA falls into.
Leap Therapeutics's current Enterprise Value is €32.70 Mil.
Leap Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-49.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Leap Therapeutics's PE Ratio for today is calculated as:
Leap Therapeutics's share price for today is €2.06.
Leap Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.970.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Leap Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:5MC has been successfully added to your 